PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 14, 2015--
Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial
results for the company’s second quarter ended June 30, 2015 will be
released before the market opens on Thursday, July 30, 2015. The Pacira
management team will host a conference call to discuss the company’s
financial results and recent and upcoming developments on Thursday, July
30, 2015, at 9 a.m. ET. The call can be accessed by dialing
1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes
prior to the start of the call and providing the Conference ID 93527661.
A replay of the call will be available approximately two hours after the
completion of the call and can be accessed by dialing 1-855-859-2056
(domestic) or 1-404-537-3406 (international) and providing the
Conference ID 93527661. The replay of the call will be available for two
weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be
accessed by visiting the “Investors & Media” section of the company’s
website at investor.pacira.com.
A replay of the webcast will be archived on the Pacira website for two
weeks following the call.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company’s flagship product,
EXPAREL® (bupivacaine liposome injectable suspension), indicated for
single-dose infiltration into the surgical site to produce postsurgical
analgesia, was commercially launched in the United States in April 2012.
EXPAREL and two other products have successfully utilized DepoFoam®, a
unique and proprietary product delivery technology that encapsulates
drugs without altering their molecular structure, and releases them over
a desired period of time. Additional information about Pacira is
available at www.pacira.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150714006277/en/
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574